Status:
RECRUITING
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
Lead Sponsor:
Peking University First Hospital
Conditions:
Chronic Kidney Disease (Stages 3b-5)
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic k...
Eligibility Criteria
Inclusion
- Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - \<45 ml/min/1.73m²)
- Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment)
- Willingness to participate in the study with signed informed consent
Exclusion
- Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months
- Unwillingness or without the ability to monitor hyperkalemia using the study device
- Patients with heart pacemaker implanted
Key Trial Info
Start Date :
April 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1066 Patients enrolled
Trial Details
Trial ID
NCT06901960
Start Date
April 2 2025
End Date
December 31 2026
Last Update
September 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
2
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
3
Hubei Provincial Hospital of TCM
Wuhan, Hubei, China, 430063